Treatment options for malignant hemangioendotheliomas of the thyroid

International Journal of Radiation Oncology, Biology, Physics
Walter RhombergGerhard Breitfellner

Abstract

Malignant hemangioendotheliomas of the thyroid are rare tumors predominantly seen in areas with endemic goiter such as the Alpine regions. The estimated incidence of the disease is between 0.15 and 0.25 per 100.000 inhabitants annually for Western Austria. The tumor is regarded as radio-resistant, and its prognosis is reported to be dismal. Between 1982 and 1999, 12 cases with immunohistochemically confirmed malignant hemangioendotheliomas of the thyroid were referred for postoperative or palliative treatment. There were 8 men and 4 women with a median age of 67 years (range, 55-81 years). With surgery, clear margins were achieved in 5, microscopic residues were left in 3, and gross residual disease in 3 patients. One patient had an inoperable primary tumor. Postoperative radiotherapy was given to 8 cases, 6 of them received the radiosensitizer razoxane on radiation days. Total tumor doses ranged between 54 and 65 Gy. Two patients with clear margins at surgery received no adjuvant radiotherapy and were observed only. Local tumor control was achieved in 11 of 12 patients; 5 lived longer than 5 years. The median survival time of all cases is presently 14 months (range, 0.5-196 months). If 3 cases with metastasis at diagnosis were...Continue Reading

References

Aug 1, 1990·The American Journal of Surgical Pathology·V EusebiJ Rosai
Dec 1, 1989·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·R E SmithD Hackbarth
Jan 1, 1983·Virchows Archiv. A, Pathological Anatomy and Histopathology·B Egloff
Dec 1, 1996·International Journal of Radiation Oncology, Biology, Physics·W RhombergD Gefeller

❮ Previous
Next ❯

Citations

Jan 13, 2006·Thyroid : Official Journal of the American Thyroid Association·I HassanA Zielke
Mar 28, 2013·Case Reports in Oncological Medicine·Kyriakos NeofytouAthanasios Petrou
Oct 18, 2018·Frontiers in Endocrinology·Michela MarinaGraziano Ceresini
Jun 30, 2019·BMJ Case Reports·Ananya KondapalliYin Oo
Nov 6, 2020·The Lancet Oncology·Sriram GubbiJoanna Klubo-Gwiezdzinska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Related Papers

Schweizerische medizinische Wochenschrift
Walter RhombergGerhard Breitfellner
American Journal of Surgery
C Y LoK Y Wan
JAMA : the Journal of the American Medical Association
Antonio Omuro, Lisa M DeAngelis
© 2021 Meta ULC. All rights reserved